David Scadden Buys Shares in Agios Pharmaceuticals

On June 18, 2026, David Scadden bought 14,950 shares of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO). This insider purchase was not part of a pre-planned trading program.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

Several insiders, including David Scadden, acquired shares of Agios Pharmaceuticals on June 18, 2026. Scadden bought 14,950 shares, while Jacqualyn Fouse, Jay Backstrom, and Rahul Ballal each also purchased 14,950 shares. Cynthia Smith acquired 2,816 shares on the same date.

Other Institutional Activity in Agios Pharmaceuticals

Institutional investors have been active in Agios Pharmaceuticals. BlackRock, Inc. increased its holdings by 519,528 shares, resulting in 5,754,957 shares valued at approximately $194.7 million. Farallon Capital Management LLC added 524,495 shares, now holding 5,684,000 shares worth about $192.3 million. State Street Corp also grew its position by 256,734 shares, totaling 3,364,879 shares valued at $113.7 million. Conversely, Armistice Capital, LLC reduced its stake by 320,000 shares, holding 2,716,000 shares worth around $91.9 million.

Agios Pharmaceuticals, Inc. Stock Up 3.8%

Shares of Agios Pharmaceuticals traded near $35.47 on Wednesday. The company has a market cap of approximately $2.09 billion and a forward P/E ratio of -7.44, indicating it's not currently profitable. Its beta of 0.587 suggests lower volatility compared to the market. The stock's 52-week range is between $22.24 and $46.00, with a 50-day moving average of $29.03 and a 200-day moving average of $31.74. Agios has a robust current ratio of 14.19 and a quick ratio of 12.80, with a debt-to-equity ratio of 3.22.

Analysts Set New Price Targets

On June 11, 2026, JP Morgan maintained a 'hold' rating for Agios with a $31.00 price target. Previously, B of A Securities reiterated a 'buy' rating with a $40.00 target on May 29, 2026. Truist Securities also maintained a 'buy' rating with a $36.00 target on April 30, 2026. The consensus among analysts is a 'buy' recommendation, with a mean price target of $40.75 based on 8 opinions.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biotech company based in Cambridge, Massachusetts. It focuses on discovering and developing medicines within the field of cellular metabolism. Its lead product, PYRUKYND (mitapivat), is used for treating hemolytic anemias in adults with pyruvate kinase deficiency and is in phase 3 trials for sickle cell disease. Agios also develops treatments for other conditions, including thalassemia and phenylketonuria (PKU).

Bottom Line

David Scadden's insider purchase of Agios Pharmaceuticals shares highlights ongoing interest in the company's potential. Institutional investors have shown mixed actions, with some increasing and others reducing their stakes. Agios is watched closely for its innovative treatments in cellular metabolism, though it currently operates at a loss as indicated by its negative forward P/E ratio.